B of A Securities Maintains Buy on Insmed, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Zemansky maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $40 to $62.
May 29, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities analyst Jason Zemansky maintains a Buy rating on Insmed and raises the price target from $40 to $62.
The Buy rating and significant increase in price target from $40 to $62 by a reputable analyst at B of A Securities is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100